Autifony Therapeutics supports art exhibition ‘Reassembling the self’, focused on schizophrenia, together with Universities of Manchester and Newcastle
Autifony Therapeutics Limited (“Autifony”), which is pioneering the development of novel pharmaceutical treatments for hearing disorders and for schizophrenia, announced that it is supporting the art exhibition ‘Reassembling the self’ focused on schizophrenia, which opens today at GV Art, the leading art-science gallery, in London. Autifony’s support reflects the company’s belief that the understanding of schizophrenia as a condition needs to be increased. The development of new and better drug treatments will require a patient-centric approach in addition to the advances being made in basic neuroscience. Autifony is joined in its support of the exhibition by the Universities of Manchester and Newcastle, with whom it is collaborating on a novel approach to treatment of schizophrenia, and by the Technology Strategy Board which is part-funding the programme.